Ending the Controversy Around Pretreatment Dihydropyrimidine Dehydrogenase (DPD/ DPYD ) Testing Heightens the Controversy Over Appropriate Fluoropyrimidine Dosing
Journal of Clinical Oncology · 01.05.2026 · 44 (13) · 1182-1185
DOI: 10.1200/jco-25-02629 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.05.2026. Verfasst von Daniel L Hertz und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI.
- University of Michigan Rogel Cancer Center, Ann Arbor, MI.
- Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA.
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA.
ORCID-Profile: Daniel L Hertz, Alan P Venook
Zitieren
APA
Hertz, D. L., & Venook, A. P. (2026). Ending the Controversy Around Pretreatment Dihydropyrimidine Dehydrogenase (DPD/ DPYD ) Testing Heightens the Controversy Over Appropriate Fluoropyrimidine Dosing. Journal of Clinical Oncology, 44(13), 1182-1185. https://doi.org/10.1200/jco-25-02629
Vancouver
Hertz DL, Venook AP. Ending the Controversy Around Pretreatment Dihydropyrimidine Dehydrogenase (DPD/ DPYD ) Testing Heightens the Controversy Over Appropriate Fluoropyrimidine Dosing. Journal of Clinical Oncology. 2026;44(13):1182-1185. doi:10.1200/jco-25-02629
BibTeX
@article{Hertz2026,
author = {Hertz, Daniel L and Venook, Alan P},
title = {Ending the Controversy Around Pretreatment Dihydropyrimidine Dehydrogenase (DPD/ DPYD ) Testing Heightens the Controversy Over Appropriate Fluoropyrimidine Dosing},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {13},
pages = {1182--1185},
doi = {10.1200/jco-25-02629}
}
EUVIMED